Currently, multiple phase 3 trials with oral semaglutide and orforglipron are ongoing for different populations (NCT05803421), while another oral GLP-1 RA (CT-996) is in early phase clinical trials (Table 1)
This table presents a clear, side-by-side evaluation of five leading Ozempic alternatives, focusing on key metrics like active ingredient, cost, dosage form, and FDA approval status
10.1152/japplphysiol.00813.2005 J Appl Physiol
For oral supplementation, 250 to 500 mg per day is the commonly studied range
:
1 v Death from cardiovascular causes, as confirmed by the event adjudication committee, includes both death from cardiovascular causes and death from undetermined causes adjudicated by that committee